GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » 10-Year Sortino Ratio

Cytophage Technologies (TSXV:CYTO) 10-Year Sortino Ratio : N/A (As of Jan. 18, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies 10-Year Sortino Ratio?

The 10-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past ten years. As of today (2025-01-18), Cytophage Technologies's 10-Year Sortino Ratio is Not available.


Competitive Comparison of Cytophage Technologies's 10-Year Sortino Ratio

For the Biotechnology subindustry, Cytophage Technologies's 10-Year Sortino Ratio, along with its competitors' market caps and 10-Year Sortino Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytophage Technologies's 10-Year Sortino Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytophage Technologies's 10-Year Sortino Ratio distribution charts can be found below:

* The bar in red indicates where Cytophage Technologies's 10-Year Sortino Ratio falls into.



Cytophage Technologies 10-Year Sortino Ratio Calculation

The 10-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last ten year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 10-Year Sortino Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past ten year.

A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.


Cytophage Technologies  (TSXV:CYTO) 10-Year Sortino Ratio Explanation

The 10-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past ten year. It is calculated as the annualized result of the average ten-year monthly excess returns divided by the standard deviation of negative returns in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.


Cytophage Technologies 10-Year Sortino Ratio Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's 10-Year Sortino Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytophage Technologies Business Description

Traded in Other Exchanges
N/A
Address
26 Henlow Bay, Winnipeg, MB, CAN, R3Y 1G4
Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.

Cytophage Technologies Headlines

No Headlines